Printed from Voxsanity (voxsanity.com.au) — NCT06145308 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Head And Neck Cancer
Phase 2 Head and Neck Cancer Trial, Recruiting
NCT06145308
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with salivary gland cancer, confirmed through a tissue sample tested in a lab
- Your tumor tissue has been tested for certain proteins (HER2, NTRK, AR, and TROP-2)
- You are generally well enough to carry out everyday activities with little or no limitation (confirm with trial site)
- You are 18 years of age or older
- Your doctors expect you to live for more than 3 months
- You have at least one area of cancer that can be measured on a scan, according to standard guidelines
- If you are a woman who could become pregnant, you have had a negative pregnancy test within 7 days before starting the trial and agree to use contraception
- Your liver, kidneys, bone marrow, heart, lungs, and other organs are working well enough to participate (confirm with trial site)
- You fully understand the trial and have signed a consent form before any study-related procedures begin
- You are able to attend all required visits and follow the trial schedule
Who may not be able to join:
- You have a known serious allergic reaction to any of the medicines used in this trial
- You had major surgery within 4 weeks before starting the trial and have not fully recovered
- You received a live vaccine within 4 weeks before the trial starts, or plan to receive any vaccine during the trial
- You have had a blood clot in an artery or vein within 6 months before starting the trial
- You have a significant heart or blood vessel condition
- You have an uncontrolled ongoing illness, such as diabetes, high blood pressure, lung scarring, liver cirrhosis, or similar conditions
- You currently have an active infection that requires treatment with medication
- You have a history of active tuberculosis
- You have tested positive for HIV
- You have chronic hepatitis B or active hepatitis C
- Your doctor believes something about your health could make the trial unsafe or difficult for you to complete
- You are pregnant, breastfeeding, or planning to have a baby during the trial period
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Recruiting
Phase
Phase 2
Sponsor
Peking Union Medical College
Registry
ClinicalTrials.gov
Start date
15 August 2023
Est. completion
10 July 2028
Where this trial is recruiting
🇨🇳 China
Primary endpoints
ORR
Can't join this trial?
Data last synced from ClinicalTrials.gov: 2 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.